Mylenda0.25 mg/0.5 ml

Mylenda 0.25 mg/0.5 ml is marketed under different brand names for different indications and in different dosage forms; the generic name alone does not identify which specific product, route, or approved use applies. Depending on the specific product:

• Subcutaneous injection (weekly) formulations are used to improve blood glucose control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise, and, in some products, to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
• Higher-dose subcutaneous injection formulations are used for chronic weight management in adults with obesity, or who are overweight with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity
• Oral tablet formulations are used to improve blood glucose control in adults with type 2 diabetes mellitus

Contains Mylenda 0.25 mg/0.5 ml as the active ingredient. It is available as a subcutaneous injection (in pre-filled pens delivering a range of weekly doses, commonly from 0.25 mg up to 2 mg for diabetes-indicated products, and higher doses for weight-management-indicated products) and as an oral tablet (commonly 3 mg, 7 mg, and 14 mg strengths). The generic name alone does not identify a single fixed strength or route; always confirm the specific product, route, and strength on its own label.

Mylenda 0.25 mg/0.5 ml is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood sugar control in type 2 diabetes and, in specific higher-dose formulations, for chronic weight management. It is available as a once-weekly subcutaneous injection and, for diabetes, also as a daily oral tablet. Treatment typically starts at a low dose and is gradually increased over several weeks to months to improve tolerability, following a defined titration schedule specific to the product and indication.

Therapeutic Class: Antidiabetic / Weight Management Agent

Mylenda 0.25 mg/0.5 ml has a half-life of approximately 1 week, supporting once-weekly subcutaneous dosing; steady-state concentrations are reached after 4-5 weeks of once-weekly dosing. The oral tablet has low absolute bioavailability (roughly 0.4-1%) and must be taken under specific conditions (empty stomach, with a small amount of water, at least 30 minutes before other food, beverages, or medicines) to ensure adequate absorption.

Subcutaneous injection

• Injected once weekly, on the same day each week, at any time of day, with or without food
• Injected into the abdomen, thigh, or upper arm; rotate injection sites
• The injection day can be changed if needed, as long as the time between two doses is at least 2 days (48 hours)
• When used with insulin, Mylenda 0.25 mg/0.5 ml and insulin may be injected in the same body region but should not be injected adjacent to each other, and should never be mixed in the same syringe

Oral tablet

• Taken once daily, first thing in the morning, on an empty stomach
• Swallowed whole with up to half a glass of plain water (about 120 mL)
• Wait at least 30 minutes before eating, drinking, or taking other oral medicines
• Do not split, crush, or chew the tablet

The following should be assessed by a healthcare professional before combining with Mylenda 0.25 mg/0.5 ml:

• Insulin or sulfonylureas, which may need dose reduction when combined with Mylenda 0.25 mg/0.5 ml, due to increased hypoglycemia risk
• Oral medicines in general, since Mylenda 0.25 mg/0.5 ml slows gastric emptying and may affect the absorption of orally administered drugs, particularly those requiring rapid gastrointestinal absorption
• Levothyroxine, whose absorption may increase when taken with the oral Mylenda 0.25 mg/0.5 ml tablet; monitoring of thyroid function may be advised
• Warfarin, where increased INR monitoring may be advisable due to potential changes in absorption

Common side effects

• Nausea, vomiting, and diarrhoea, particularly during dose escalation
• Decreased appetite
• Constipation
• Abdominal pain
• Injection site reactions (for the injectable form)

Serious side effects (seek urgent medical attention)

• Signs of acute pancreatitis: severe abdominal pain, sometimes radiating to the back, with nausea or vomiting
• Signs of gallbladder disease: pain in the upper right abdomen, fever, yellowing of the skin or eyes
• Signs of a thyroid tumor: a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath
• Signs of severe hypoglycemia, especially if used with insulin or a sulfonylurea
• Signs of acute kidney injury, often related to dehydration from severe vomiting or diarrhoea
• Signs of a severe allergic reaction: swelling of the face or throat, difficulty breathing
• Changes in vision, particularly in patients with existing diabetic retinopathy

Pregnancy

Mylenda 0.25 mg/0.5 ml may cause fetal harm based on animal data, and weight loss during pregnancy offers no benefit and may cause fetal harm. Discontinue Mylenda 0.25 mg/0.5 ml when pregnancy is recognized, and use effective contraception during treatment, as advised by the treating physician; because of its long duration of action, discontinuation is generally recommended at least 2 months before a planned pregnancy.

Breastfeeding

It is not known whether Mylenda 0.25 mg/0.5 ml passes into human milk; use during breastfeeding should be discussed with a healthcare professional, weighing the mother's need for treatment against any potential infant exposure.

• Thyroid C-cell tumors: Mylenda 0.25 mg/0.5 ml causes thyroid C-cell tumors in rodents; its relevance to humans has not been determined. Counsel patients on the potential risk of medullary thyroid carcinoma and symptoms of thyroid tumors.
• Acute pancreatitis: Observed in clinical trials; discontinue promptly if pancreatitis is suspected.
• Diabetic retinopathy complications: Reported with rapid improvement in glucose control; monitor patients with a history of diabetic retinopathy.
• Hypoglycemia: Risk is increased when combined with insulin or insulin secretagogues; dose reduction of these other agents may be needed.
• Acute kidney injury: Can occur, often related to dehydration from gastrointestinal side effects; maintain adequate fluid intake.
• Acute gallbladder disease: Has been reported; evaluate promptly if symptoms occur.

Overdose may cause more pronounced gastrointestinal side effects, such as severe nausea and vomiting, and, in patients on concomitant insulin or sulfonylureas, an increased risk of hypoglycemia. Suspected overdose should be evaluated by a healthcare professional; treatment is generally supportive, appropriate to the clinical presentation.

Store unused injection pens in a refrigerator at 2°C to 8°C; do not freeze. After first use, the pen may generally be stored at room temperature (below 30°C) or refrigerated, for a period specified by the manufacturer, with the pen cap on. Store oral tablets at room temperature, protected from moisture, in the original container.

• Renal impairment: No dose adjustment is generally required, though the medicine has not been extensively studied in severe renal impairment; monitor renal function, particularly if gastrointestinal side effects cause dehydration.
• Hepatic impairment: No dose adjustment is generally required for mild to moderate impairment; caution is advised in severe impairment.
• Elderly: No specific dose adjustment based on age alone.

Mylenda 0.25 mg/0.5 ml is generally used as ongoing, long-term therapy for type 2 diabetes or, for the relevant products, chronic weight management, for as long as clinically indicated and tolerated, with the maintenance dose and continuation determined by the treating physician based on response and tolerability.

Drug Class: Glucagon-like peptide-1 (GLP-1) receptor agonist

Mylenda 0.25 mg/0.5 ml activates GLP-1 receptors, which increases insulin secretion in a glucose-dependent manner, reduces glucagon secretion, and slows gastric emptying. These combined effects lower blood glucose and, particularly at the higher doses used for weight management, promote satiety and reduced food intake, supporting weight loss.

Some Mylenda 0.25 mg/0.5 ml subcutaneous injection products are approved for use in adolescents 12 years and older for the specific approved indication (type 2 diabetes or, in relevant products, weight management), under specialist supervision; safety and efficacy of the oral tablet have not been established in patients younger than 18 years. Pediatric use should follow the specific product's own approved labeling and a specialist's guidance.